Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Z. Chen
Based on 6 articles published since 2010
(Why 6 articles?)
||||

Between 2010 and 2020, Z. Chen wrote the following 6 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. 2015

Geng, Y / Qi, Q / Sun, M / Chen, H / Wang, P / Chen, Z. ·Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. · Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China. · Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. Electronic address: wangp413@163.com. · Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. Electronic address: zchenzl@fudan.edu.com. ·Eur J Surg Oncol · Pubmed #26343824.

ABSTRACT: BACKGROUND: Recent studies have implied a prognostic value of the prognostic nutritional index (PNI) in certain types of human cancers. However, the value of PNI for predicting survival in patients with pancreatic cancer remains unknown. The goal of this study was to investigate the predictive significance of PNI in patients with advanced pancreatic cancer. METHODS: A total of 321 consecutive patients with pathologically-confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) were retrospectively recruited between January 2011 and August 2013. The patients were divided into a test set (n = 110) and a validation set (n = 211). We evaluated the association between PNI and overall survival (OS). The relationship between PNI and systemic inflammatory response markers, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) was also assessed. In addition, the associations between PNI and the TNF-α were analyzed. RESULTS: Kaplan-Meier analyses showed that a low PNI correlated significantly with a shorter OS in patients with advanced pancreatic cancer (190 days for patients with a low PNI vs. 290 days for patients with a high PNI, log-rank = 12.566, P < 0.001). Multivariate analysis identified PNI as an independent prognostic factor for OS (hazard ratio [HR]: 0.627, 95% confidence interval [CI]: 0.453-0.868, P = 0.003). PNI also correlated positively with NLR and PLR and negatively with LMR. Additionally, patients with a low PNI exhibited high levels of TNF-α. CONCLUSIONS: Our results confirm that PNI is associated with the systemic inflammatory response and can be used to predict survival in advanced pancreatic cancer.

2 Article Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. 2015

Qi, Q / Geng, Y / Sun, M / Wang, P / Chen, Z. ·Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. · Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China. · Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. Electronic address: wangp413@163.com. · Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, 130 Dong An Road, Shanghai 200032, China. Electronic address: cz.chenzhen@gmail.com. ·Pancreatology · Pubmed #25641673.

ABSTRACT: BACKGROUND: Cancer-associated inflammation is a key molecular feature of pancreatic ductal adenocarcinoma. In this study, we systematically evaluated the prognostic relevance of systemic inflammatory response (SIR) markers in patients with advanced pancreatic cancer. METHODS: A total of 321 consecutive patients with pathologically-confirmed locally advanced or metastatic pancreatic adenocarcinoma were retrospectively recruited. The patients were divided into a test set (n = 110) and a validation set (n = 211). The associations between overall survival (OS) and clinically available SIR markers including white blood cell (WBC) count, absolute neutrophil count, absolute lymphocyte count, absolute monocyte count, platelet count, neutrophil-lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and lymphocyte/monocyte ratio (LMR) were analyzed using Kaplan-Meier curves and multivariate Cox proportional models. RESULTS: High WBC count, neutrophil count, monocyte count, NLR, PLR and low LMR were significantly associated with decreased OS in the test set. Using the validation set for confirmation, we found also in multivariate analysis an independent value of WBC count (hazard ratio (HR): 2.176, 95% confidence interval (CI): 1.560-3.035, P < 0.001), neutrophil count (HR: 2.807, 95% CI: 2.000-3.940, P < 0.001), monocyte count (HR: 1.848, 95% CI: 1.315-2.598, P < 0.001), NLR (HR: 2.204, 95% CI: 1.590-3.055, P < 0.001), PLR (HR: 1.537, 95% CI: 1.114-2.122, P = 0.009) and LMR (HR: 0.569, 95% CI: 0.412-0.784, P = 0.001) for OS in patients with advanced pancreatic cancer. CONCLUSIONS: Our study confirmed that SIR markers can be used to determine optimal therapeutic strategies for individual patients and to predict pancreatic cancer prognosis.

3 Article Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized control trials. 2014

Chen, Z / Song, X / Yang, D / Li, Y / Xu, K / He, Y. ·Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. · Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Electronic address: bigo_sysu@163.com. ·Eur J Surg Oncol · Pubmed #25079195.

ABSTRACT: BACKGROUND: Postoperative pancreatic fistula (PF) is the leading morbidity after pancreaticoduodenectomy (PD). The pancreatoenteric anastomosis method after PD is associated with the occurrence of PF. Evidence shows that pancreaticogastrostomy (PG) is possibly superior to pancreaticojejunostomy (PJ) in reducing the incidence of PF after PD; however, this remains to be definitively confirmed. METHODS: Randomized clinical trials (RCTs) comparing the outcomes of PG versus PJ after PD were retrieved for meta-analysis. RESULTS: After a thorough search of the English literature published until March 23rd, 2014, we identified seven RCTs involving 1095 patients (PG group, 548; PJ group, 547) for final analysis. Meta-analysis revealed that the incidence of PF was significantly lower in the PG group (15.7%) than in the PJ group (23.0%, 126/547; OR = 0.61, 95% CI: 0.45-0.83, P = 0.002). Furthermore, the incidence of intra-abdominal fluid collection was also lower in the PG group than in the PJ group (OR = 0.43, 95% CI: 0.28-0.65, P < 0.0001). No significant differences were found between the PG and PJ groups in terms of delayed gastric emptying, hemorrhage, overall morbidity and mortality. CONCLUSIONS: PG seemed to be superior to PJ in reducing the incidence of PF and intra-abdominal fluid collection after PD.

4 Article Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. 2014

Wang, P / Chen, L / Zhang, J / Chen, H / Fan, J / Wang, K / Luo, J / Chen, Z / Meng, Z / Liu, L. ·1] Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [2] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. · Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China. · Central Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China. ·Oncogene · Pubmed #23334332.

ABSTRACT: Previous studies have demonstrated that microRNA (miRNA) expression is altered in human cancer. However, the molecular mechanism underlying these changes in miRNA expression remains unclear. In this study, we investigated the epigenetic modification of miR-124 genes and the potential function of miR-124 in pancreatic cancer. Using pyrosequencing analysis, we found that miR-124 genes (including miR-124-1, miR-124-2 and miR-124-3) are highly methylated in pancreatic cancer tissues compared with in non-cancerous tissues. Hypermethylation mediated the silencing of miR-124, which was a frequent event in pancreatic duct adenocarcinoma (PDAC). Furthermore, miR-124 downregulation was significantly associated with worse survival of PDAC patients. Functional studies showed that miR-124 inhibited cell proliferation, invasion and metastasis. Furthermore, we characterized Rac1 as a direct target of miR-124, and miR-124 interacted with the 3'-untranslated region of Rac1, which we showed to be a putative tumor promoter in pancreatic cancer. Thus, the miR-124-mediated downregulation of Rac1 led to the inactivation of the MKK4-JNK-c-Jun pathway. Therefore, our study demonstrates that miR-124 is a tumor suppressor miRNA that is epigenetically silenced in pancreatic cancer. Our findings suggest a previously unidentified molecular mechanism involved in the progression and metastasis of pancreatic cancer.

5 Article K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. 2010

Chen, H / Tu, H / Meng, Z Q / Chen, Z / Wang, P / Liu, L M. ·Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China. ·Eur J Surg Oncol · Pubmed #20542658.

ABSTRACT: OBJECTIVE: To determine the prognostic value of K-ras mutations in plasma DNA of unresectable pancreatic cancer patients. METHODS: Blood samples were collected from 91 patients with unresectable pancreatic cancer prior to treatment. K-ras gene was amplified from the circulating plasma DNA. Mutations were detected by direct sequencing. The relationship between the types of K-ras gene and prognosis of unresectable pancreatic cancer was evaluated. RESULTS: K-Ras codon 12 mutations were found in 30 of 91(33%) plasma DNA samples, 17mutations were c.35G>A (p.G12D), 11 were c.35G>T (p.G12V) and only 2 were c.34G>C (p.G12R)). K-ras codon 12 mutations could significantly reflect the clinical parameters, including TNM tumor staging (P=0.033) and liver metastasis (P=0.014). The median survival time of patients with K-ras mutations was shorter than that of patients with wild-type K-ras gene (3.9 months vs. 10.2 months, P<0.001). K-ras codon 12 mutation from plasma DNA was an independent negative prognostic factor for survival (hazard ratio, 7.39; 95% confidence interval, 3.69-14.89). CONCLUSION: K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of unresectable pancreatic cancer patients.

6 Minor Reply to: Should we consider pancreaticogastrostomy the best method of reconstruction after pancreaticoduodenectomy? 2016

Chen, Z / Song, X / He, Y. ·Department of Gastrointestinal Surgery Centre, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. · Department of Gastrointestinal Surgery Centre, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address: bigo_sysu@163.com. ·Eur J Surg Oncol · Pubmed #26718328.

ABSTRACT: -- No abstract --